<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The Women's Health Initiative (WHI) study of postmenopausal hormone therapy (HT) found that <z:chebi fb="0" ids="50114">estrogen</z:chebi> plus <z:chebi fb="13" ids="50745">progestogen</z:chebi> therapy (EPT) decreased <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, the decline in EPT use from 2002 to 2003 should have precipitated an increase in the incidence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We tested this prediction using the SEER 9 epidemiologic database </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We analyzed WHI data concerning the effects of EPT and <z:chebi fb="0" ids="50114">estrogen</z:chebi> therapy (ET) on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risks </plain></SENT>
<SENT sid="4" pm="."><plain>We also examined HT prescription sales data, as well as SEER 9 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidences from 2001 to 2004 </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In the WHI study, the incidence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> was comparable in EPT placebo-users, ET users, and ET placebo-users, but significantly lower in EPT users </plain></SENT>
<SENT sid="6" pm="."><plain>Assuming that 30% of eligible women used HT in 2001, the decline in EPT sales from 2002 to 2003 of 63% should have increased the incidence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> by 2.8% in the overall population at risk </plain></SENT>
<SENT sid="7" pm="."><plain>However, the SEER 9 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence fell by 5.9% in this population, which is comparable to the 6.7% decrease observed for invasive <z:hpo ids='HP_0003002'>breast cancer</z:hpo> from 2002 to 2003 </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Declining EPT use from 2002 to 2003 should have precipitated an increase in the incidence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but the opposite trend was seen in the SEER 9 database during this time </plain></SENT>
<SENT sid="9" pm="."><plain>The incidences of invasive <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> both declined by a similar amount from 2002 to 2003, despite the results of the WHI study predicting opposing trends for the two different types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, the SEER 9 findings are fundamentally incompatible with expectations from the WHI findings </plain></SENT>
<SENT sid="11" pm="."><plain>This implies that reductions in HT use from 2002 to 2003 cannot account for the contemporaneous changes in invasive <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> incidences </plain></SENT>
<SENT sid="12" pm="."><plain>Alternative explanations must be found </plain></SENT>
</text></document>